ProQR Therapeutics
PRQR
29 hedge funds and large institutions have $46.9M invested in ProQR Therapeutics in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 7 closing their positions.
9% less funds holding
Funds holding: 32 → 29 (-3)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
52% less capital invested
Capital invested by funds: $97.1M → $46.9M (-$50.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$8.51M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$1.84M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$560K |
| 4 |
O
OrbiMed
New York
|
+$173K |
| 5 |
FO
FT Options
Chicago,
Illinois
|
+$63.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.3M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$5.05M |
| 3 |
Millennium Management
New York
|
-$2.03M |
| 4 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
-$1.73M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Morgan Stanley
New York
| $5K | +$5.08K | +1,000 | New |
|
|
HHMI
27
Howard Hughes Medical Institute
Chevy Chase,
Maryland
| $3K | -$356 | -70 | -9% |
|
|
TRCT
28
Tower Research Capital (TRC)
New York
| $3K | +$2.62K | +515 | +464% |
|
29
Creative Planning
Overland Park,
Kansas
| $2K | – | – | – |
|
|
30
Viking Global Investors
Stamford,
Connecticut
| – | -$5.05M | -581,668 | Closed |
|
|
SFM
31
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.3M | -150,000 | Closed |
|
|
PC
32
Polar Capital
London,
United Kingdom
| – | -$260K | -30,000 | Closed |
|
|
ARTA
33
A.R.T. Advisors
New York
| – | -$244K | -28,202 | Closed |
|
|
SIM
34
Spark Investment Management
New York
| – | -$190K | -21,900 | Closed |
|
35
Citadel Advisors
Miami,
Florida
| – | -$103K | -11,960 | Closed |
|
36
UBS Group
Zurich,
Switzerland
| – | -$8K | -957 | Closed |
|
PRQR Hedge Fund Activity: Q1 2016 in Review
29 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q1 2016, worth a combined $46.9M — down 52% from $97.1M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PRQR and 4 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Jennison Associates, adding an estimated $8.51M. The largest seller was Fidelity Investments, cutting an estimated $10.3M.
- 29 institutional investors held ProQR Therapeutics (PRQR) as of Q1 2016, down from 32 in Q4 2015.
- Funds reported $46.9M of ProQR Therapeutics stock for Q1 2016, down 52% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q1 2016 and 7 closed out, a net change of -3 holders.
- The largest ProQR Therapeutics buyer in Q1 2016 was Jennison Associates, an estimated $8.51M added.
- The largest ProQR Therapeutics seller in Q1 2016 was Fidelity Investments, an estimated $10.3M sold.
Based on aggregated 13F filings for Q1 2016.